Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Krystal Biotech (KRYS) Accumulated Depreciation & Amortization: 2021-2025

Historic Accumulated Depreciation & Amortization for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $29.2 million.

  • Krystal Biotech's Accumulated Depreciation & Amortization rose 47.40% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.0 million, marking a year-over-year increase of 56.55%. This contributed to the annual value of $21.9 million for FY2024, which is 70.88% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Accumulated Depreciation & Amortization is $29.2 million, which was up 9.44% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Accumulated Depreciation & Amortization ranged from a high of $29.2 million in Q3 2025 and a low of $2.8 million during Q1 2021.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $17.4 million (2024), whereas its average is $17.7 million.
  • Data for Krystal Biotech's Accumulated Depreciation & Amortization shows a peak YoY skyrocketed of 91.74% (in 2024) over the last 5 years.
  • Over the past 5 years, Krystal Biotech's Accumulated Depreciation & Amortization (Quarterly) stood at $4.2 million in 2021, then skyrocketed by 61.20% to $6.8 million in 2022, then soared by 88.83% to $12.8 million in 2023, then soared by 70.88% to $21.9 million in 2024, then soared by 47.40% to $29.2 million in 2025.
  • Its Accumulated Depreciation & Amortization was $29.2 million in Q3 2025, compared to $26.7 million in Q2 2025 and $24.3 million in Q1 2025.